Indivior has suffered a critical defeat in the US courts for opioid addiction product Suboxone Film, opening the door to generic competition and sparking a run on its shares.
Pfizer has lost its protracted patent battle in the UK for big-selling drug Lyrica, potentially exposing it to claims for hundreds of millions of pounds from the NHS.
Novartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD)
It all looked so good in 2011 when Eli Lilly agreed a deal with French biotech Adocia to develop an ultra-rapid insulin, in a deal worth up to $165 million.
The UK government has outlined how it will ensure the supply of medicines continues in the event of a “no deal” Brexit, urging companies to stockpile six weeks' worth of medicine.<
Novartis is aiming to draw a line under a scandal involving payments to Donald Trump's former lawyer with a new ethics chief - Siemens' former compliance head Klaus Moosmayer.